Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Smithfield Foods Fourth Quarter 2025 Earnings Call - Record profits, tight leverage, big Sioux Falls build and Nathan's deal set to accelerate growth
Smithfield closed 2025 with an operational hat trick, delivering record adjusted operating profit of $1.3 billion, expanded margins, and roughly $1 billion of adjusted net income while sitting on a fo...
- Record 2025 financials: adjusted operating profit rose 30% to $1.3 billion, with adjusted operating margin expanding to 8.6% from 7.2% in 2024.
- Adjusted net income from continuing operations was roughly $1.0 billion for 2025, and adjusted diluted EPS was $2.55, up 36% year over year.
- Fourth quarter highlights: adjusted operating profit of $402 million and adjusted net income of $329 million, the company’s second highest quarterly net income on record.
- +11 more takeaways
LENZ Therapeutics Q4 2025 Earnings Call - VIZZ proves effective in early launch, but category build will take time
LENZ walked investors through five months of the VIZZ (LNZ100) launch with a clear message, confident metrics, and a healthy war chest. The product is delivering fast, observable benefit in the clinic...
- Product efficacy confirmed in real world: VIZZ (LNZ100) produces rapid, noticeable improvement in near vision for many patients, often within about 30 minutes and lasting up to ~10 hours.
- Early commercial traction: since launch through end of the quarter LENZ sold over 45,000 monthly packs and recorded more than 20,000 paid and filled prescriptions in the first quarter of sales.
- Broad prescriber footprint: more than 10,000 eye care professionals have prescribed VIZZ, exceeding comparable early-stage launches like Miebo and Vuity at the same point.
- +12 more takeaways
Core & Main Q4 and Full Year 2025 Earnings Call - Gaining Share and Margins with Meters, Treatment and Private Label as Residential Stalls
Core & Main closed fiscal 2025 with durable cash flow and share gains even as end markets were uneven. Net sales were $7.65 billion, Adjusted EBITDA $931 million, adjusted diluted EPS $2.97, and opera...
- Core & Main reported FY2025 net sales of $7.65 billion, Adjusted EBITDA of $931 million, adjusted diluted EPS of $2.97, and operating cash flow of $650 million.
- The company delivered its 16th consecutive year of sales growth and estimates roughly 20% U.S. market share in a ~$44 billion addressable market (U.S. and Canada).
- End-market mix: municipal 44% of sales, non-residential ~38%, residential lot development ~18%. Municipal volumes were up low- to mid-single digits, non-residential roughly flat, and residential down low double digits in FY2025.
- +14 more takeaways
Achieve Life Sciences Q4 2025 Earnings Call - NDA Accepted, PDUFA Set for June 20; Aims for 1H 2027 U.S. Launch with Onshore Manufacturing
Achieve Life Sciences spent 2025 moving cytisinicline from a development story to a near-commercial company. The company confirmed NDA acceptance and a PDUFA date set for June 20, while securing a Com...
- NDA for cytisinicline was submitted and accepted, management confirms the PDUFA date remains set for June 20.
- Achieve received a Commissioner’s National Priority Voucher for the vaping cessation indication, which should shorten FDA review from a typical 10-12 months to an accelerated 1-2 month timeline for that pathway.
- Company plans a U.S. commercial launch in the first half of 2027, contingent on securing product supply and completing remaining launch-ready operations.
- +12 more takeaways
Fennec Pharmaceuticals Q4 and Full Year 2025 Earnings Call - Record Sales, Commercial Ramp and Patent Settlement Extends Exclusivity to 2033
Fennec closed 2025 with clear commercial momentum and a cleaner balance sheet. Net product sales jumped to $44.6 million for the year, a roughly 50% increase versus 2024, and Q4 sales came in at $13.8...
- Net product sales were $13.8 million in Q4 2025, up ~75% from $7.9 million in Q4 2024; full year 2025 net product sales were $44.6 million versus $29.6 million in 2024, about a 50% increase.
- Fennec attributes growth to quarter-over-quarter expansion in active patients, new and existing account uptake, and stronger conversion and adherence driven by commercial execution.
- The Fennec HEARS patient support program hit record enrollments, prescribed and infused vials, active patients, and improved conversion rates, rising from roughly 50% in Q1 to ~70% in Q4.
- +12 more takeaways
Vertical Aerospace FY2025 Earnings Call - Full Transition Imminent, but Cash Runway Forces Capital Strategy
Vertical says Valo is finally in the home stretch. Piloted transition is in the tail end of testing, conducted under direct U.K. CAA oversight, and the company expects closure of the remaining flight ...
- Piloted transition is in the final innings, described as the tail of the S-curve, with less than 10% of transition test points remaining and management expecting completion imminently once weather and final data checks align.
- Flight testing is being conducted under disciplined U.K. CAA oversight using the companys DOA procedures, effectively running a prototype certification dry run to reduce downstream certification risk.
- Weather was a material drag on testing in early 2026, including a run of roughly 46 rain days that delayed flight opportunities and extended the timeline.
- +13 more takeaways
Cadeler Q3 2025 Earnings Call - EUR 2.8bn backlog, 2027 fully booked as company pivots to full-scope foundation T&I
Cadeler closed 2025 ahead of guidance, reporting a beefy EUR 2.8 billion backlog, strong utilization and a EUR 425 million EBITDA for the year. Management is shifting the company from a charter/day-ra...
- Backlog at EUR 2.8 billion at year-end 2025, providing multi-year earnings visibility; management says 80% of the backlog has reached final investment decision.
- 2025 financials ahead of guidance: reported revenue around EUR 620 million, EBITDA EUR 425 million and net profit EUR 280 million.
- Operational execution: Four new builds delivered on time and on budget in 2025; fleet average age now five years and Cadeler claims the largest, most versatile fleet in the market.
- +14 more takeaways
Heidmar Maritime Q4 2025 Earnings Call - Red Sea disruption turbocharges tanker rates, Q1 set to be a record
Heidmar reported sharp revenue growth in 2025 driven by a larger managed fleet, short-term charters and the April 2025 start of PSV ACE, yet posted a full-year loss after a string of non-cash charges ...
- Q4 revenue rose to $25.1 million, up from $5.3 million in Q4 2024, driven by managed fleet growth, more short-term voyage and time charters, and PSV ACE starting operations in April 2025.
- Full-year 2025 revenue jumped to $55.9 million from $29.0 million in 2024, reflecting fleet expansion and stronger freight markets.
- Continuing operations net loss for 2025 was $8.6 million, versus net income of $1.9 million in 2024, pulled down by $5.0 million of stock-based compensation amortization and $3.9 million of unrealized earn-out fair value expense.
- +12 more takeaways
Lument Finance Trust Fourth Quarter 2025 Earnings Call - CLO Boosts Liquidity but Reserves and REO Keep Dividend Under Pressure
Lument closed Q4 2025 with a stopgap of liquidity and fresh paper after executing the LMNT 2025-FL3 CLO, but headline performance was mixed. GAAP net loss was $0.17 per share, distributable earnings w...
- Q4 GAAP net loss was $0.17 per common share; distributable earnings were approximately $0.00 for the quarter.
- Board declared and maintained a quarterly dividend of $0.04 (Q4 2025 and Q1 2026); cumulative dividends for 2025 totaled $0.22 per share.
- LMNT 2025-FL3 CLO closed in December: $664 million transaction, effective advance rate ~88%, weighted average cost of funds ~SOFR + 191 bps, 30-month reinvestment period through June 2028.
- +12 more takeaways
Hesai Group Q4 2025 Earnings Call - GAAP Profitability and a 3-3.5M 2026 Shipment Leap
Hesai closed 2025 as the first lidar vendor to report a full-year GAAP profit, delivering CNY 436 million in net income on CNY 3+ billion of revenue and a 1.6 million unit shipment run rate. Managemen...
- Hesai reported industry-first full-year GAAP net income of CNY 436 million for 2025, with full-year revenue just over CNY 3 billion, up 46% year-over-year.
- Shipments accelerated to about 1.6 million units in 2025, including nearly 240,000 robotics lidars; management raised 2026 shipment guidance to 3.0–3.5 million units.
- Gross margin remained above 40% in 2025, operating expenses (ex-other operating income) fell by CNY 88 million despite strong revenue growth, and operating cash flow was positive CNY 117 million.
- +12 more takeaways